Literature DB >> 16382041

Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1.

Sarki A Abdulkadir1.   

Abstract

Recent developments in the generation and analysis of transgenic mouse models have improved our understanding of the early stages of prostate tumorigenesis. Analysis of models based on the homeodomain protein Nkx3.1 and the zinc finger protein Egr1 suggests that these transcription factors play distinct roles in the initiation and progression of precursor prostatic intraepithelial neoplasia (PIN) lesions, respectively. Nkx3.1 is a candidate prostate tumor suppressor gene (TSG) that demonstrates haploinsufficiency. Disruption of one or both copies of the murine Nkx3.1 gene leads to the development of epithelial hyperplasia and PIN. This appears to be a consequence of delayed exit from the cell cycle by differentiating prostate luminal epithelial cells in Nkx3.1 mutant mice. Gene expression profiling has provided additional insight into the basis of haploinsufficiency in Nkx3.1 mutant mice. A reduction in Nkx3.1 dosage leads to dramatic alterations in the expression of a subset of genes by altering the probability of a target gene existing in the "on" or "off" state. The immediate early gene Egr1, on the other hand, is overexpressed in human and mouse prostate tumors and PIN lesions and regulates the expression of several genes implicated in prostate tumor progression, including platelet-derived growth factor and insulin-like growth factor II. Prostate cancer-prone mice lacking Egr1 exhibit a significant delay in tumor progression. Specifically, Egr1 deficiency impairs the transition from PIN to invasive carcinoma. Thus, Nkx3.1 and Egr1 regulate gene programs involved in distinct aspects of prostate tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382041     DOI: 10.1196/annals.1339.018

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

1.  NKX3.1 as a marker of prostatic origin in metastatic tumors.

Authors:  Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

2.  An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells.

Authors:  Xu-Bao Shi; Lingru Xue; Joy Yang; Ai-Hong Ma; Jianjun Zhao; Ma Xu; Clifford G Tepper; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

Review 3.  Prostate cancer epigenome.

Authors:  Swathi Chinaranagari; Pankaj Sharma; Nathan J Bowen; Jaideep Chaudhary
Journal:  Methods Mol Biol       Date:  2015

Review 4.  The progress of early growth response factor 1 and leukemia.

Authors:  Jing Tian; Ziwei Li; Yang Han; Tao Jiang; Xiaoming Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2016-05

5.  Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70.

Authors:  Yi Peng; Caihong X Li; Fei Chen; Zhengxin Wang; Martin Ligr; Jonathan Melamed; Jianjun Wei; William Gerald; Michele Pagano; Michael J Garabedian; Peng Lee
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

6.  Egr-1 promotes cell proliferation and invasion by increasing β-catenin expression in gastric cancer.

Authors:  Ting Sun; Hua Tian; Yu-Guang Feng; Ya-Qin Zhu; Wei-Qian Zhang
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

7.  Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer.

Authors:  Heyu Zhang; Michael H Muders; Jinping Li; Francesca Rinaldo; Donald J Tindall; Kaustubh Datta
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 8.  Is EGR1 a potential target for prostate cancer therapy?

Authors:  Delphine Gitenay; Véronique T Baron
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

9.  Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

Authors:  Martin B Oleksiewicz; Jennifer Southgate; Lars Iversen; Frederikke L Egerod
Journal:  PPAR Res       Date:  2009-01-28       Impact factor: 4.964

10.  Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip.

Authors:  Shilpi Arora; Yipeng Wang; Zhenyu Jia; Saynur Vardar-Sengul; Ayla Munawar; Kutbuddin S Doctor; Michael Birrer; Michael McClelland; Eileen Adamson; Dan Mercola
Journal:  Genome Biol       Date:  2008-11-25       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.